CNBC Pro

Morgan Stanley downgrades Bristol-Myers Squibb on drug pipeline concern

The New York Stock Exchange welcomes Bristol Myers Squibb on Nov. 20th, 2020.
NYSE

Uncertainty around drug developments could hold back the price of Bristol-Myers Squibb stock, according to Morgan Stanley.

Analyst David Risinger downgraded the stock to equal weight from overweight on Friday, saying the long-term picture for the company's earnings power was getting less positive.

More In Street Calls

Goldman Sachs' Currie says oil stocks are trading 'far below' their long-term trend
CNBC ProGoldman Sachs' Currie says oil stocks are trading 'far below' their long-term trend
Tesla's stock is suffering from Musk's Twitter takeover, Morgan Stanley survey of investors finds
CNBC ProTesla's stock is suffering from Musk's Twitter takeover, Morgan Stanley survey of investors finds
Here are Tuesday's biggest analyst calls: Apple, Amazon, Tesla, Disney, Roku, Boeing, UPS & more
CNBC ProHere are Tuesday's biggest analyst calls: Apple, Amazon, Tesla, Disney, Roku, Boeing, UPS & more